Showing 2271-2280 of 5771 results for "".
- OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113 in a Mouse Model of Dry Eye Diseasehttps://modernod.com/news/okyo-pharma-announces-potent-anti-inflammatory-effects-of-ok-113-in-a-mouse-model-of-dry-eye-disease/2476830/OKYO Pharma has announced potent anti-inflammatory activity of OK-113, an in-house discovered proprietary agonist of Chemerin GPCR, in an experimental model of dry eye disease (DED) in mice. These preclinical efficacy data, identifying a lead drug candidate, will facilitate initiation of clinical
- Staar Surgical Announces FDA IDE Clinical Study Approvalhttps://modernod.com/news/staar-surgical-announces-fda-ide-clinical-study-approval/2476825/Staar Surgical announced that the FDA, in a letter dated August 23, 2019, stated that it has determined that Staar has provided sufficient data to support initiation of a human clinical study in the United States of the EVO/EVO+ Visian Implantable Collamer Lens for myopia, and EVO/EVO+ Visian Tor
- Quantel Medical Announces Acquisition of Optotek Medicalhttps://modernod.com/news/quantel-medical-announces-acquisition-of-optotek-medical/2476821/Quantel Medical announced that it is acquiring ophthalmic medical device maker Optotek Medical. This acquisition comes after a long collaboration between the two companies through the development and supply of devices
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)https://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-1123-in-patients-with-autosomal-dominant-retinitis-pigmentosa-adrp/2476802/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-1123. ProQR plans to start enrolling patients in a phase 1/2 trial for QR-1123 in 2019. QR-1123 is a first-in-class investigational oligonucleotide designed to address the underlying
- TopiVert Announces Topline Results from Phase 2b/3 Study of Dry Eye Disease Drug Candidatehttps://modernod.com/news/topivert-announces-topline-results-from-theia-1-phase-2b-3-clinical-study-of-top1630-as-a-treatment-for-dry-eye-disease/2476792/TopiVert Pharma announced topline results from THEIA-1 phase 2b/3 clinical study evaluating TOP1630, a novel anti-inflammatory kinase inhibitor, as an ophthalmic solution for the treatment of dry eye disease. THEIA-1, a multicenter, randomized, double-masked, placebo-controlled phase 2b/3
- Alimera Announces Iluvien Regulatory Approval in Australia for the Treatment of DMEhttps://modernod.com/news/alimera-announces-iluvien-regulatory-approval-in-australia-for-the-treatment-of-dme/2479552/Alimera Sciences announced that the Australian Therapeutic Goods Administration (TGA), the division of the Australian Department of Health that oversees the availability of medical products, has approved Iluvien (190 micrograms intravitreal implant in applicator) for the treatment of diabetic mac
- Staar Surgical Announces Submission of Presbyopia Clinical Trial Datahttps://modernod.com/news/staar-surgical-announces-submission-of-presbyopia-clinical-trial-data/2479554/Staar Surgical announced the submission of its multisite European pivotal clinical trial data for the EVO+ Visian ICL with Aspheric (EDOF) Optic, a lens that is designed to provide correction or reduction of myopia or hyperopia and presbyopia. Results from the clinical trial were submitted to DEK
- Clearside Biomedical Announces Multiple Presentations Delivered at the ASRS Annual Meetinghttps://modernod.com/news/clearside-biomedical-announces-multiple-presentations-delivered-at-the-asrs-annual-meeting/2479557/Clearside Biomedical announced that multiple oral presentations were delivered on Clearside’s pipeline and proprietary SCS Microinjector targeting the suprachoroidal space (SCS) at the American Society of Retinal Specialists (ASRS) Annual Meeting. “Clearside had a widespread presence at t
- BioTime Announces Name Change to Lineage Cell Therapeuticshttps://modernod.com/news/biotime-announces-name-change-to-lineage-cell-therapeutics/2479562/In a move to reflects the company’s commitment to becoming a leading cell therapy company, BioTime announced it is launching a new corporate brand, including a change of its corporate name to Lineage Cell Therapeutics, effective August 12, 2019. In connection with the launch, the com
- Kodiak Sciences Announces Positive Interim Data from Phase 1b Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-announces-positive-interim-data-from-phase-1b-study-of-ksi-301-a-novel-anti-vegf-antibody-biopolymer-conjugate-for-treatment-of-retinal-diseases/2476775/Kodiak Sciences announced positive interim results from the ongoing phase 1b study of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate in patients with anti-VEGF treatment-naïve wet age-related macular degeneration (AMD), diabetic mac